Trial Profile
A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-9857 in Subjects With Normal Renal Function and Severe Renal Impairment
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Mar 2020
Price :
$35
*
At a glance
- Drugs Voxilaprevir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Gilead Sciences
- 17 Apr 2016 Preliminary results presented at The International Liver Congress™ 2016
- 13 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Sep 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.